Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2023 Net Income-$8.24M-$8.24MN/M vs Q2 2023 EPS Diluted-$2.78-$2.78no prior Q2 2023 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flowderived-$623,654N/M ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end